What are the side effects of Lurbinectedin?

In clinical studies of Lurbinectedin in the treatment of small cell lung cancer, the most common adverse reaction (including laboratory abnormalities) (≥20%) was leukopenia , lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, decreased thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium, and diarrhea. After Rubicatin was put on the market, adverse events such as extravasation including tissue necrosis requiring debridement, rhabdomyolysis, and tumor lysis syndrome occurred.